2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Status
Completed
2
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
4
Conditions
Breast Neoplasms
576
Carcinoma, Non-Small-Cell Lung
490
Ovarian Neoplasms
328
Lung Neoplasms
208
Fallopian Tube Neoplasms
153
Neoplasms
152
Stomach Neoplasms
128
Esophageal Neoplasms
127
Triple Negative Breast Neoplasms
125
Neoplasm Metastasis
120
Carcinoma, Ovarian Epithelial
115
Squamous Cell Carcinoma of Head and Neck
96
Endometrial Neoplasms
95
Uterine Cervical Neoplasms
80
Head and Neck Neoplasms
78
Esophageal Squamous Cell Carcinoma
76
Adenocarcinoma of Lung
49
Recurrence
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
45
Melanoma
42
Carcinoma
42
Urinary Bladder Neoplasms
41
Adenocarcinoma Of Esophagus
36
Small Cell Lung Carcinoma
34
Carcinoma, Squamous Cell
34
Prostatic Neoplasms
32
Pancreatic Neoplasms
30
Breast Neoplasms, Male
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Adenocarcinoma, Bronchiolo-Alveolar
26
Interventions
Paclitaxel
4
liposomal doxorubicin
3
Carboplatin
3
pembrolizumab
2
Bevacizumab
2
1-dodecylpyridoxal
2
poly(I).poly(c12,U)
1
mirabegron
1
disitamab vedotin
1
apatinib
1
anlotinib
1
Tocotrienols
1
Platinum Compounds
1
Lenalidomide
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
EP-100 membrane-disrupting peptide
1
Cisplatin
1
AC 7700
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Ovarian Cancer Recurrent
×
Paclitaxel
×
Clear all
NCT06843447
2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
460 enrolled
NCT04072263
2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2
Unknown
12 enrolled
NCT01332656
2015-12-21
OPSALIN
Sanofi
Phase 2
Completed
154 enrolled
NCT01485848
2014-06-10
ESP2011-002
Esperance Pharmaceuticals Inc
Phase 2
Completed
49 enrolled